Total Payments
$717,441
2024 Payments
$7,170
Companies
14
Transactions
359
Medicare Patients
1,381
Medicare Billing
$131,121
Payment Breakdown by Category
Research$636,127 (88.7%)
Other$66,790 (9.3%)
Consulting$7,795 (1.1%)
Food & Beverage$3,752 (0.5%)
Travel$2,967 (0.4%)
Education$10.28 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $636,127 | 199 | 88.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $66,790 | 28 | 9.3% |
| Consulting Fee | $7,795 | 4 | 1.1% |
| Food and Beverage | $3,752 | 102 | 0.5% |
| Travel and Lodging | $2,967 | 25 | 0.4% |
| Education | $10.28 | 1 | 0.0% |
Payments by Type
Research
$636,127
199 transactions
General
$81,314
160 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $716,518 | 330 | $0 (2024) |
| RedHill Biopharma Inc. | $184.67 | 10 | $0 (2022) |
| Janssen Pharmaceuticals, Inc | $156.23 | 5 | $0 (2019) |
| Amarin Pharma Inc. | $155.28 | 2 | $0 (2017) |
| Merck Sharp & Dohme Corporation | $120.82 | 1 | $0 (2019) |
| Allergan Inc. | $117.28 | 1 | $0 (2019) |
| ABBVIE INC. | $50.92 | 3 | $0 (2022) |
| Valeant Pharmaceuticals North America LLC | $30.28 | 1 | $0 (2017) |
| Alfasigma USA, Inc. | $23.95 | 1 | $0 (2020) |
| VBI Vaccines (Delaware) Inc. | $22.04 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $7,170 | 12 | Gilead Sciences, Inc. ($7,170) |
| 2023 | $6,356 | 14 | Gilead Sciences, Inc. ($6,356) |
| 2022 | $10,504 | 18 | Gilead Sciences, Inc. ($10,390) |
| 2021 | $40,420 | 26 | Gilead Sciences, Inc. ($40,324) |
| 2020 | $64,663 | 43 | Gilead Sciences, Inc. ($64,589) |
| 2019 | $114,920 | 61 | Gilead Sciences, Inc. ($114,636) |
| 2018 | $175,455 | 74 | Gilead Sciences, Inc. ($175,332) |
| 2017 | $297,955 | 111 | Gilead Sciences Inc ($297,723) |
All Payment Transactions
359 individual payment records from CMS Open Payments — Page 1 of 15
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/07/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $4.60 | General |
| 10/09/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $1.75 | General |
| 07/18/2024 | Gilead Sciences, Inc. | Vemlidy (Drug) | Travel and Lodging | In-kind items and services | $45.38 | General |
| Category: HBV | ||||||
| 07/15/2024 | Gilead Sciences, Inc. | Vemlidy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,030.00 | General |
| Category: HBV | ||||||
| 07/12/2024 | Gilead Sciences, Inc. | Vemlidy (Drug) | Food and Beverage | In-kind items and services | $107.66 | General |
| Category: HBV | ||||||
| 07/12/2024 | Gilead Sciences, Inc. | Vemlidy (Drug) | Travel and Lodging | In-kind items and services | $15.48 | General |
| Category: HBV | ||||||
| 05/24/2024 | Gilead Sciences, Inc. | Vemlidy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,030.00 | General |
| Category: HBV | ||||||
| 05/08/2024 | Gilead Sciences, Inc. | Vemlidy (Drug) | Food and Beverage | In-kind items and services | $121.32 | General |
| Category: HBV | ||||||
| 05/02/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $2.97 | General |
| 04/24/2024 | Gilead Sciences, Inc. | Vemlidy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $800.00 | General |
| Category: HBV | ||||||
| 04/04/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $5.10 | General |
| 01/20/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $5.40 | General |
| 12/09/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $5.00 | General |
| 11/06/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $19.73 | General |
| 08/16/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $6.61 | General |
| 07/10/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $4.75 | General |
| 06/06/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $14.96 | General |
| 05/25/2023 | Gilead Sciences, Inc. | Vemlidy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,000.00 | General |
| Category: HBV | ||||||
| 05/23/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $2.60 | General |
| 05/17/2023 | Gilead Sciences, Inc. | Vemlidy (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: HBV | ||||||
| 03/29/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $20.13 | General |
| 02/15/2023 | Gilead Sciences, Inc. | Vemlidy (Drug) | Travel and Lodging | In-kind items and services | $15.00 | General |
| Category: HBV | ||||||
| 02/09/2023 | Gilead Sciences, Inc. | Vemlidy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,000.00 | General |
| Category: HBV | ||||||
| 02/07/2023 | Gilead Sciences, Inc. | Vemlidy (Drug) | Food and Beverage | In-kind items and services | $119.70 | General |
| Category: HBV | ||||||
| 02/04/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $4.50 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Positive, Chronic Hepatitis B | Gilead Sciences, Inc. | $169,024 | 60 |
| A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Tenofovir Alafenamide (TAF) versus Tenofovir Disoproxil Fumarate (TDF) in Virologically Suppressed Subjects with Chronic HBV | Gilead Sciences Inc | $147,645 | 17 |
| A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Tenofovir Alafenamide (TAF) versus Tenofovir Disoproxil Fumarate (TDF) in Virologically Suppressed Subjects with Chronic HBV | Gilead Sciences, Inc. | $137,381 | 28 |
| A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety and Efficacy of GS-9620 in combination with Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Subjects with Chronic Hepatitis B and who are currently not on Treatment | Gilead Sciences, Inc. | $72,896 | 37 |
| A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Positive, Chronic Hepatitis B | Gilead Sciences Inc | $53,441 | 14 |
| A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Negative, Chronic Hepatitis B | Gilead Sciences, Inc. | $28,626 | 24 |
| A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 in combination with Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Subjects with Chronic Hepatitis B and who are currently not on Treatment | Gilead Sciences, Inc. | $15,374 | 9 |
| A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Negative, Chronic Hepatitis B | Gilead Sciences Inc | $8,328 | 7 |
| A Long Term Follow-up Registry Study of Subjects Treated in Gilead-Sponsored Trials with Chronic Hepatitis B Infection | Gilead Sciences, Inc. | $3,412 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 299 | 318 | $190,300 | $30,226 |
| 2022 | 7 | 322 | 340 | $186,000 | $30,766 |
| 2021 | 8 | 404 | 432 | $203,900 | $41,024 |
| 2020 | 6 | 356 | 413 | $166,340 | $29,105 |
Total Patients
1,381
Total Services
1,503
Medicare Billing
$131,121
Procedure Codes
29
All Medicare Procedures & Services
29 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 73 | 88 | $22,000 | $6,804 | 30.9% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 33 | 34 | $44,200 | $6,592 | 14.9% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 47 | 47 | $49,350 | $4,545 | 9.2% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 42 | 42 | $29,400 | $4,464 | 15.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 35 | 35 | $14,000 | $3,092 | 22.1% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 37 | 37 | $14,800 | $2,026 | 13.7% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2023 | 12 | 12 | $10,800 | $1,441 | 13.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 20 | 23 | $5,750 | $1,262 | 21.9% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 28 | 28 | $36,400 | $5,694 | 15.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 57 | 66 | $16,500 | $5,546 | 33.6% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 49 | 49 | $51,450 | $5,144 | 10.0% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 43 | 43 | $30,100 | $4,998 | 16.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 70 | 70 | $28,000 | $4,253 | 15.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 59 | 68 | $17,150 | $3,153 | 18.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 16 | 16 | $6,400 | $1,980 | 30.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 118 | 141 | $17,000 | $8,300 | 48.8% |
| 45380 | Biopsy of the large bowel using an endoscope (colonoscopy) | Facility | 2021 | 66 | 66 | $69,300 | $7,383 | 10.7% |
| 45385 | Removal of polyps or growths in large bowel using an endoscope (colonoscopy) using a mechanical snare | Facility | 2021 | 32 | 32 | $41,600 | $6,791 | 16.3% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2021 | 55 | 57 | $39,900 | $6,513 | 16.3% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 75 | 75 | $15,000 | $5,428 | 36.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 31 | 34 | $5,100 | $3,137 | 61.5% |
| 45378 | Diagnostic examination of the colon (large bowel) using an endoscope(colonoscopy); high risk | Facility | 2021 | 14 | 14 | $12,600 | $2,067 | 16.4% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 13 | 13 | $3,400 | $1,406 | 41.3% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope | Facility | 2020 | 33 | 34 | $44,200 | $7,361 | 16.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 123 | 172 | $20,640 | $6,589 | 31.9% |
About Dr. Xiaoli Ma, MD
Dr. Xiaoli Ma, MD is a Gastroenterology healthcare provider based in Philadelphia, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/06/2006. The National Provider Identifier (NPI) number assigned to this provider is 1558300152.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Xiaoli Ma, MD has received a total of $717,441 in payments from pharmaceutical and medical device companies, with $7,170 received in 2024. These payments were reported across 359 transactions from 14 companies. The most common payment nature is "" ($636,127).
As a Medicare-enrolled provider, Ma has provided services to 1,381 Medicare beneficiaries, totaling 1,503 services with total Medicare billing of $131,121. Data is available for 4 years (2020–2023), covering 29 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Philadelphia, PA
- Active Since 06/06/2006
- Last Updated 08/11/2011
- Taxonomy Code 207RG0100X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1558300152
Products in Payments
- Vemlidy (Drug) $613,879
- Talicia (Drug) $184.67
- Vascepa (Drug) $155.28
- INVOKANA (Drug) $142.45
- STEGLATRO (Drug) $120.82
- ZENPEP (Drug) $117.28
- LINZESS (Drug) $38.45
- XIFAXANIBSD (Drug) $30.28
- PreHevbrio (Drug) $22.04
- XIFAXAN (Drug) $16.33
- OCALIVA (Drug) $15.49
- FibroScan (Device) $14.77
- Amitiza (Drug) $14.62
- XARELTO (Drug) $13.78
- Creon (Drug) $12.47
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Philadelphia
Gary Lichtenstein, Md, MD
Gastroenterology — Payments: $416,696
Gastroenterology $416,696
Dr. Neilanjan Nandi, Md, MD
Gastroenterology — Payments: $334,815
Gastroenterology $334,815
Dr. David Lichtenstein, M.d, M.D
Gastroenterology — Payments: $263,694
Gastroenterology $263,694
James Lewis, Md, MD
Gastroenterology — Payments: $229,188
Gastroenterology $229,188
Mark Osterman, Md, MD
Gastroenterology — Payments: $142,430
Gastroenterology $142,430
Dr. Oleg Volchonok, M.d, M.D
Gastroenterology — Payments: $116,291
Gastroenterology $116,291